<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226131</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103552</org_study_id>
    <nct_id>NCT04226131</nct_id>
  </id_info>
  <brief_title>MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics</brief_title>
  <acronym>MusculRA</acronym>
  <official_title>MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persons with rheumatoid arthritis (RA) suffer from increased disability and mortality, in
      part resulting from skeletal muscle impairments. In this study, our objective is to determine
      if skeletal muscle biomechanical properties are altered in RA. Up to 15 participants with
      early RA defined as duration of disease/symptoms of less than 6 months (where &quot;duration&quot;
      denotes the length of time the patient has had symptoms/disease, not the length of time since
      RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD)
      therapy and 15 age-, sex-, and BMI-matched controls will undergo clinical assessments of
      skeletal muscle stiffness and elasticity as measured by the hand-held MyotonPro device.
      Additional study participant assessments include cardiopulmonary exercise testing, muscle
      strength testing, body composition measurement using BodPod, muscle oxidative capacity
      testing using near-infrared spectroscopy, and thigh muscle needle biopsies to compare
      clinical findings to an ex vivo cultured myobundle system. Primary statistical analyses will
      be comparisons of skeletal muscle parameters in RA compared to controls and correlations to
      determine relationships between variables. Thigh muscle biopsies are a low-risk procedure
      that may cause minor local soreness and bleeding; all other clinical assessments are
      non-invasive and will induce minimal discomfort to participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Up to 30 adults, 25-75 yrs. of age may be recruited and enrolled to participate
      in a cross-sectional study. Subjects will be divided between two cohorts: 1) persons with
      early RA (n=15) and 2) age-, sex-, Body Mass Index (BMI)-matched healthy controls (n=15). The
      goal is to have equal numbers between groups complete the study. Early RA defined as duration
      of disease/symptoms of less than 6 months (where &quot;duration&quot; denotes the length of time the
      patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to
      starting biologic DMARD therapy were chosen to minimize the effect of medications on skeletal
      muscle.

      Demographics and comorbidities will be assessed via self-report during an initial phone
      screening interview, with confirmation from the computerized medical record. Once it has been
      determined that the subject meets pre-screening criteria, they will be scheduled for Visit-1.

      Phone Pre-Screening: Once the phone screening is complete and the subject appears to meet all
      of the study criteria, a REDCap web address will be sent to the participant via email in
      order to complete study questionnaires online about their overall health, pain, fatigue,
      physical function, sleep and ability to manage their disease.

      Study participants will undergo the following at Visit 1:

      Consent: The consent visit will take place at the Duke Center for Living and will last
      approximately three hours. The study staff will explain the study and the consent form in
      detail. Once the required consent documentation has been signed and dated appropriately, the
      subject will undergo the following:

        -  Brief medical history including list of medications

        -  PROMIS Measures (If unable to complete online prior to Visit-1)

        -  Anthropometric Measurements: Height/Weight/Body Mass Index

        -  Vitals: Resting Blood Pressure and Heart Rate

        -  Fasting Blood Draw

        -  Physician RA Joint Assessment: Disease Activity (DAS-28) Assessment

        -  MyotonPro Skeletal Muscle Biomechanical Assessments

        -  NIRS Muscle Oxidative Capacity Test

        -  Muscle Biopsy

        -  BodPod and Minimal Waist Circumference

      Brief Medical History and Medication Review: A brief medical history including list of
      medications will be performed by study staff.

      Questionnaires: Using Duke's REDCap (Research Electronic Data Capture) interface, a battery
      of Patient-Reported Outcomes Measurement Information System (PROMIS) self-reported health
      outcome measures has been added to a computerized interface and will be associated with this
      investigation. Measures include global health, pain, fatigue, physical function,
      self-efficacy for disease management and sleep. Of note, staff testing of this battery
      indicated this could be completed between 10 and 12 minutes; the investigators project
      participants may take longer, expecting approximately 30 minutes. Except for global health,
      scoring is performed by the computerized REDCap interface. Specific measure names and
      versions as listed in REDCap are listed below:

        -  PROMIS SF v1.1 Global Health

        -  PROMIS SF v2.0 Physical Function 20a

        -  PROMIS Scale v1.0 Pain Intensity 3a

        -  PROMIS SF v1.0 General Life Satisfaction 5a

        -  PROMIS Bank v1.0 Short Form Fatigue 8a

        -  Stanford Brief Activity Survey

      Visit 2 Assessments:

        -  Cardiopulmonary Exercise Test

        -  Strength Tests

             -  Leg Extension Machine - Quadriceps / Hamstrings Strength

             -  Hand Dynamometer - Grip Strength
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>15 participants with early RA defined as duration of disease/symptoms of less than 6 months (where &quot;duration&quot; denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic DMARD therapy and 15 age-, sex-, and BMI-matched controls</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle stiffness and elasticity</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine whether passive skeletal muscle stiffness (Newtons/meters) and elasticity (logarithmic decrement) are different in RA compared to matched healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myobundle function</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine whether myobundle function, including force production and tissue stiffness (kPa), in RA differs compared to controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Janus kinase/signal transducers and activators of transcription 3 pathway (JAK/STAT3) signaling in skeletal muscle</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine whether JAK/STAT3 signaling is upregulated in RA skeletal muscle compared to controls.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Early RA defined as duration of disease/symptoms of less than 6 months (where &quot;duration&quot; denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic Disease-modifying anti-rheumatic drugs (bDMARD) therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Controls.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>A study nurse will draw up to 50 mL of blood to measure erythrocyte sedimentation rate (ESR) and measures of immune cell function. ESR is a common hematology test that is a measure of inflammation.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Disease Activity (DAS-28) Assessment</intervention_name>
    <description>Participants in the RA cohort will receive a 28-joint examination by the study physician to assess RA disease activity and report their overall health assessment.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skeletal Muscle Mitochondrial Respiratory Capacity</intervention_name>
    <description>Near-Infrared Spectroscopy (NIRS) will be used to measure oxidative capacity of forearm flexor digitorum profundus and medial gastrocnemius muscles using the PortaMon device (Artinis Medical Systems, The Netherlands). NIRS is a low-cost, non-invasive method that estimates muscle oxidative capacity by measuring oxygen consumption (mVO2) recovery kinetics via assessment of intramuscular oxy- and deoxy-hemoglobin concentration following a sequence of brief, rapid arterial cuff occlusions. NIRS measures mitochondrial oxidative function as the mVO2 recovery rate constant k. In the absence of blood flow, changes in muscle oxygenation occur via oxygen consumption alone. In persons without RA, this non-invasive approach is highly correlated with muscle respiratory capacity assessed via muscle biopsies using in situ permiabilized fiber bundles and the Oroboros O2k system.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
    <other_name>Near-Infrared Spectroscopy (NIRS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle Biopsy</intervention_name>
    <description>After local anesthesia (xylocaine, 2%) is injected, a small incision will be made in the thigh. Four to six small pieces of muscle about the size of a pea will be surgically removed. The incision site will be closed using steri-strips and/or derma-bond, and a light dressing applied.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Body Composition</intervention_name>
    <description>Body composition assessments include circumference measurements and the BOD PODÂ®. Minimal waist circumference measurements will be taken using a tape measure.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiopulmonary Exercise Test (CPET)</intervention_name>
    <description>Cardiorespiratory aerobic capacity (VO2 peak), will be assessed using a maximal treadmill test protocol with cardiopulmonary gas exchange. Subjects will be asked to exercise on a treadmill to their perceived maximum ability and effort during which time they will have a mouthpiece in their mouth to determine maximal oxygen use/consumption through breathing. For safety purposes the subject will be monitored by electrocardiogram (ECG) and their blood pressure will be measured at rest and throughout the exercise phase of this test.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strength Testing</intervention_name>
    <description>Strength assessments will include dynamometry-assessed grip and quadriceps strength (Cybex HUMAC NORM, Comp Sports Med, Inc., Stoughton, MA) tests</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Measures include global health, pain, fatigue, physical function, self-efficacy for disease management and sleep.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skeletal Muscle Biomechanical Property Assessment</intervention_name>
    <description>Passive skeletal muscle stiffness and elasticity measurements of bilateral biceps brachii, flexor carpi radialis, vastus lateralis, and tibialis anterior using mechanical deformation with myotonometry using the MyotonPro device.</description>
    <arm_group_label>Age-, Sex-, BMI-matched Healthy Controls</arm_group_label>
    <arm_group_label>Early Rheumatoid Arthritis (RA)</arm_group_label>
    <other_name>Myotonometry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Study participants will include 25-75 year-old adults with early
        rheumatoid arthritis and healthy age-, gender-, and BMI-matched controls.

          -  Rheumatoid arthritis participants will all be seropositive (positive rheumatoid factor
             or anti-citrullinated protein antibody) or with erosions typical of RA on radiographs.

          -  Meet 2010 American College of Rheumatology/European League Against Rheumatism
             (ACR/EULAR) Classification Criteria for RA.

          -  Early RA defined as duration of disease/symptoms of less than 6 months (where
             &quot;duration&quot; denotes the length of time the patient has had symptoms/disease, not the
             length of time since RA diagnosis) AND prior to starting biologic DMARD therapy.

          -  Participants will not be engaging in regular exercise (According to 2018 US
             guidelines): not more than 150 minutes per week of moderate intensity exercise or 75
             minutes per week of vigorous intensity exercise) for at least three months prior to
             consent.

        Exclusion Criteria:

          -  Early RA participants will be excluded if they have already started bDMARD therapy.

          -  The investigators will exclude persons using non-aspirin anticoagulants that would
             complicate the biopsy. There will be a wash-out period of seven days for anti-platelet
             agents, and three days for NSAIDs prior to biopsies.

          -  Uncontrolled thyroid diseases

          -  Chronic obstructive lung disease

          -  Parkinson's disease

          -  Ankylosing spondylitis

          -  Congestive Heart Failure Class III and above will be excluded based on recognized
             effects on skeletal muscle.

          -  Patients with absolute or relative contraindications to exercise will be excluded:
             recent (&lt;6 months) acute cardiac event, unstable angina, uncontrolled dysrhythmias
             causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled
             symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis,
             suspected or known dissecting aneurism or acute systemic infection, left main coronary
             stenosis, moderate stenotic valvular heart disease, outflow tract obstruction, high
             degree atrioventricular (AV) block, ventricular aneurysm.

          -  Uncontrolled metabolic disease (e.g. diabetes, thyrotoxicosis, myxoedema)

          -  Uncontrolled pulmonary disease (e.g. severe COPD or pulmonary fibrosis)

          -  Mental or physical impairment leading to inability to exercise adequately

          -  Pregnant women will be excluded as determined via menstrual history/self-reporting.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim M Huffman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucy W Piner, MS</last_name>
    <phone>919-660-6781</phone>
    <email>lucy.piner@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim M Huffman, MD</last_name>
    <phone>919-668-1644</phone>
    <email>kim.huffman@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke Medicine - Duke Molecular Physiology Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucy W Piner, MS</last_name>
      <phone>919-660-6781</phone>
      <email>lucy.piner@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Kim M Huffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian J Andonian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skeletal Muscle</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

